[New Year's Address] John Lim, CEO of Samsung Biologics: "We Will Solidify Unrivaled Competitiveness"

"A Higher Level of Competitiveness Will Be Required in Every Aspect"

John Lim, President and CEO of Samsung Biologics, emphasized in his New Year's address on January 2 that the company will further enhance execution excellence centered on its core values of '4E (Excellence)' and the '3S' strategy to strengthen competitiveness.

President Lim began by saying, "2026 is the Year of the Red Horse and marks the 15th anniversary of our founding. Just like the horse, which symbolizes tireless passion, drive, and strength, I hope that all of us, as One Team, will make a powerful leap toward our goal of becoming the global No.1 CDMO (Contract Development and Manufacturing Organization)."

John Lim, President and CEO of Samsung Biologics. Samsung Biologics

He cited last year's achievements, including the completion of the company split, securing land for the 3rd Bio Campus in Songdo, and the acquisition of the Rockville plant in the United States, stating, "We have established a solid foundation to support our mid- to long-term growth." He emphasized that this foundation should be used to further solidify the company's unrivaled competitive edge.

Regarding the external environment, Lim mentioned the growing global economic and geopolitical uncertainties and intensifying industry competition, diagnosing that "this year will require an even higher level of competitiveness in every aspect."

President Lim stressed the need to improve execution excellence centered on the 4E and 3S strategies in order to maintain a competitive edge.

He stated, "The 4E should serve as the standard for all decisions and actions," highlighting the importance of Customer Excellence, Quality Excellence, Operational Excellence, and People Excellence.

In particular, regarding quality, he emphasized, "Quality is the absolute standard in the bio industry, which deals with life, and it is our mission to uphold it without compromise under any circumstances." On the operational efficiency front, he called for the active use of digital technologies such as AI to achieve tangible improvements that can be felt in the field.

As an execution strategy to translate the 4E into real outcomes, Lim introduced the 3S approach, urging the company to enhance execution speed and quality and operational stability through Simplification and Standardization, and to continue pursuing a growth strategy based on Scalability.

Samsung Biologics will continue its three-pronged expansion strategy in 2026, focusing on production capacity, portfolio, and global bases. The company plans to accelerate global business expansion using the Rockville plant in the United States as a new base and to further enhance its capabilities in new modalities.

In particular, the antibody-drug conjugate (ADC) and organoid businesses, which officially launched last year, will be further advanced this year and developed into key pillars supporting future growth.

Concluding his New Year's address, President Lim asked employees to "do your utmost in your respective roles with pride and a sense of mission in safeguarding humanity's life and future," and encouraged everyone by wishing for "a year filled with both challenges and achievements."